Raising Funds for Growth Investments and Financial Improvement Through Stock Acquisition Rights
First written in FY2019-Q1. 3 of 5 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2021-Q2.
4 other companies' latest entry also says "Restated".
- FY2021-Q2RestatedAnnual report
「There were no applicable matters concerning the exercise of stock acquisition rights with provisions for revision of the exercise price or related bonds during the current second-quarter cumulative consolidated period.」
Regarding funding through stock acquisition rights, no new exercise or fundraising during the quarter was disclosed, and no material change to the existing fundraising plan was identified. - FY2019AdvancedAnnual report
「During the fourth-quarter accounting period, 42,393 stock acquisition rights with provisions for revision of the exercise price were exercised, resulting in the delivery of 4,239,300 shares and funds raised of ¥4,119 million. Funds raised during the 90th fiscal year totaled ¥6,759 million.」
Exercise of the stock acquisition rights progressed, raising 65,000 rights and ¥6,759 million cumulatively for the fiscal year. Capital strengthening for research and development, mass-production capacity and capital investment, and repayment of short-term borrowings has moved into the execution phase. - FY2019-Q3AdvancedAnnual report
「During the accounting period, 17,412 stock acquisition rights with provisions for revision of the exercise price were exercised, resulting in the delivery of 1,741,200 shares and funds raised of ¥1,827 million. The cumulative number of such stock acquisition rights and related bonds exercised as of the end of the accounting period was 22,607, and cumulative funds raised were ¥2,639 million.」
Exercise of the stock acquisition rights progressed, raising ¥1,827 million during the third-quarter accounting period and ¥2,639 million cumulatively. Stated capital and capital surplus also each increased by ¥1,329 million. - FY2019-Q2AdvancedAnnual report
「To raise funds for executing its growth strategy, the Company issued stock acquisition rights through a third-party allotment and began strengthening its capital through the issuance of new shares. During the second-quarter accounting period, 5,195 stock acquisition rights with provisions for revision of the exercise price were exercised, resulting in the delivery of 5,195,000 shares and funds raised of ¥812 million.」
Following the issuance of stock acquisition rights through a third-party allotment, 5,195 were exercised during the quarter, raising ¥812 million. Stated capital and capital surplus each increased by ¥408 million, and capital strengthening for growth investment, capital investment and repayment of short-term borrowings has moved into the execution phase. - FY2019-Q1First statedAnnual report
「At a meeting of the Board of Directors held on 6 August 2018, the Company resolved to issue, by way of a third-party allotment, the first series of stock acquisition rights with provisions for revision of the exercise price, as follows. Amount of funds raised (value of assets contributed upon exercise of the stock acquisition rights): ¥12,200,900,000 (approximate net proceeds). ① Research and development expenses for new products to drive medium- to long-term growth ② Capital investment to establish mass-production capacity for newly developed products, improve the performance and quality of existing products, and achieve further rationalization and efficiency ③ Repayment of short-term borrowings to improve the soundness of the financial structure」
The Company resolved to issue, by way of a third-party allotment, stock acquisition rights with provisions for revision of the exercise price, and initially described plans to use approximate net proceeds of ¥12.209 billion for research and development of new products, capital investment to establish mass-production capacity and improve existing products, and repayment of short-term borrowings. The exercise period is from 23 August 2018 to 31 August 2021.